| Literature DB >> 31497334 |
Aki Vuokko1, Kirsi Karvala1, Hille Suojalehto1, Harri Lindholm2, Sanna Selinheimo1, Marja Heinonen-Guzejev3, Sami Leppämäki4, Sebastian Cederström5, Christer Hublin1, Katinka Tuisku5, Markku Sainio1.
Abstract
BACKGROUND: Chronic nonspecific symptoms attributed to indoor nonindustrial work environments are common and may cause disability, but the medical nature of this disability is unclear. The aim was to medically characterize the disability manifested by chronic, recurrent symptoms and restrictions to work participation attributed to low-level indoor pollutants at workplace and whether the condition shares features with idiopathic environmental intolerance.Entities:
Keywords: Building-related intolerance; Disability evaluation; Environmental intolerance; Functional somatic syndromes; Indoor air
Year: 2019 PMID: 31497334 PMCID: PMC6717934 DOI: 10.1016/j.shaw.2019.06.003
Source DB: PubMed Journal: Saf Health Work ISSN: 2093-7911
Assessment and evaluation methods
| Occupational and psychosocial functioning | |
| Self-assessed current work ability | Q |
| Own prognosis regarding being able to work two years from now | Q |
| The Social and Occupational Functioning Assessment Scale | I |
| Sheehan Disability Scale, subdomains work, social life, home | Q |
| Shirom-Melamed Burnout Measure | Q |
| Respiratory functioning, inflammation, and allergy | |
| Peak Expiratory Flow monitoring for two weeks | M |
| Flow-volume spirometry (Spirostar USB Medikro, Finland) | M |
| Exhaled lower respiratory nitric oxide and nasal nitric oxide | M |
| Bronchial hyperresponsiveness | M |
| Skin prick tests to common environmental allergens and molds (ALK-Abello, Hørsholm, Denmark; Stallergenes SA, Antony, France) | M |
| Asthma Control Test (ACT) | Q |
| Autonomic nervous system function and hypothalamic–pituitary–adrenal axis functioning | |
| Cardiovascular tests | M |
| Hyperventilation provocation test | M |
| Long-term recording of heart rate variability in beat-to-beat intervals | M |
| Salivary cortisol (LIA, IBL Hamburg, Germany) | M |
| Psychiatric symptoms and functioning and personality | |
| Structured Clinical Interview for DSM-IV Disorders (I and II) | I |
| Yale-Brown Obsessive Compulsive Scale | I |
| Montgomery–Åsberg Depression Rating Scale | I |
| Generalized Anxiety Disorder 7-item Scale | Q |
| Beck Anxiety Inventory | Q |
| Overall Anxiety Severity and Impairment Scale | Q |
| The Patient Health Questionnaire-9 | Q |
| Beck Depression Inventory | Q |
| Insomnia Severity Index | Q |
| Other characteristics | |
| Demographics (e.g. age, gender, marital status, education, work, sick leave) | I + Q |
| Health condition, current symptoms, pain, diseases, medication | I + Q |
| The Quick Environmental Exposure and Sensitivity Inventory | |
| Chemical Intolerance | Q |
| Intolerance to indoor air molds | Q |
| Environmental-related health concerns | Q |
| Indoor air quality at workplace and home | I + Q |
I, interview; M, medical investigation; Q, questionnaire.
Scale from 0 (total work disability) to 10 (work ability at its best).
Options “fairly sure”, “not sure”, or “hardly”.
Scale 1–100: 51–70 (moderate or some difficulty), 71–80 (slight impairment), 81–100 (good or superior functioning).
Each subdomain on a scale 0–10: 0 (not at all disability), 1–3 (mildly), 4–6 (moderately), 7–9 (markedly), 10 (extremely).
Mean of the 14 items, each item on a scale 1–7: 1 (never or almost never), 2 (very infrequently), 3 (quite infrequently), 4 (sometimes), 5 (quite frequently), 6 (very frequently), 7 (always or almost always).
The Finnish version of the ACT. The ACT is a trademark of Quality Metric Incorporated 2002 GlaxoSmithKline.
Each item on a scale 0–10: 0 (not at all a problem), 5 (moderate symptoms), 10 (disabling symptoms).
Each item on a scale 0–10: 0 (not at all), 5 (moderately), 10 (severely).
Scale from 0 (not at all concern) to 10 (extremely concern).
Demographic characteristics and workplace adjustments made
| All ( | |
|---|---|
| Female, | 11 |
| Age, years, mean (SD) | 49.8 (6.0) |
| Married or cohabitation, | 12 |
| Education | |
| High level, | 6 |
| Mid level, | 3 |
| Basic, | 3 |
| Nonsmoker, | 11 |
| Body mass index, kg/m2, mean (range) | 26.9 (21.3–36.3) |
| Work absence days during preceding 12 months | |
| Owing to any reason, days, mean (range) | 92.4 (2–365) |
| Owing to indoor air–related symptoms, days, mean (range) | 88.6 (0–365) |
| Physician visits during preceding 12 months | |
| For any reason, number, mean (range) | 14.8 (2–40) |
| For indoor air–related symptoms, number, mean (range) | 13.0 (0–36) |
| Duration of indoor air–related symptoms, years (range) | 10.5 (2–25) |
| Workplace adjustments | |
| Relocation, | 11 |
| Working timetable arrangement, | 1 |
| Sabbatical leave, | 4 |
| Remote work, | 3 |
| Part-time work, | 2 |
| Working as a freelancer in several jobs, | 1 |
SD, standard deviation.
An individual may have one or more measures.
Self-reported environmental intolerances and concerns, mean (range)
| All ( | |
|---|---|
| QEESI | |
| Chemical Intolerance score | 50.1 (4–91) |
| Life Impact score | 55.5 (1–94) |
| Intolerance to indoor molds | 8.7 (0–10) |
| Intolerance to EMFs | 0.8 (0–6) |
| Health concerns regarding | |
| Environmental exposures | 8.8 (3–10) |
| Indoor air exposures at workplace | 9.4 (7–10) |
EMFs, electromagnetic fields; QEESI, the Quick Environmental Exposure and Sensitivity Inventory.
Sum score 0–100.
Scale 0–10.
Self-rated symptoms of anxiety, depression, insomnia, and burnout
| All ( | ||
|---|---|---|
| Anxiety | GAD-7, mean (range) | 4.8 (0–13) |
| Mild anxiety (score 5–9), | 3 | |
| Moderate anxiety (score 10–14), | 3 | |
| BAI, mean (range) | 7.0 (0–16) | |
| Mild anxiety (score 8–15), | 4 | |
| Moderate anxiety (score 16–25), | 1 | |
| OASIS, mean (range) | 3.1 (0–10) | |
| Identification of clinical anxiety (score ≥ 8), | 1 | |
| Depression | PHQ-9, mean (range) | 5.0 (0–12) |
| Mild depression (score 5–9), n | 4 | |
| Moderate depression (score 10–14), n | 2 | |
| BDI, mean (range) | 7.2 (1–17) | |
| Mild depression (score 14–19), n | 2 | |
| Insomnia | ISI, mean (range) | 9.3 (0–27) |
| Subthreshold insomnia (score 8–14), n | 4 | |
| Moderate severity insomnia (score 15–21), n | 1 | |
| Severe insomnia (score 22–28), n | 1 | |
| Burnout | SMBM total, mean (range) | 2.9 (1.4–4.6) |
| Mild or moderate burnout (score 2.3–3.7), n | 5 | |
| Severe burnout (score ≥ 3.8), n | 2 |
BAI, Beck Anxiety Inventory (sum score 0–63); BDI, Beck Depression Inventory (sum score 0–63); GAD-7, Generalized Anxiety Disorder (sum score 0–21); ISI, Insomnia Severity Index (sum score 0–28); OASIS, Overall Anxiety Severity and Impairment Scale (sum score 0–20); PHQ-9, Patient Health Questionnaire-9 (sum score 0–27); SMBM, Shirom-Melamed Burnout Measure (score 1–7).
n = 10.
n = 11.
n = 9, three patients who were on sick leave were excluded.
Current somatic diseases and psychiatric disorders based on clinical evaluation and medical history.
| Somatic diseases | |
|---|---|
| Asthma | 6 |
| Benign arrhythmia | 1 |
| Fibromyalgia | 1 |
| Hypothyreosis (controlled by medication) | 2 |
| Irritable colon syndrome | 2 |
| Anal fissure | 1 |
| Migraine | 2 |
| Musculoskeletal disorder | 4 |
| Psychiatric disorders | |
| Anxiety disorders | |
| Social phobia | 1 |
| Specified phobic anxiety disorder | 1 |
| Other specified anxiety disorder | 4 |
| Reaction to severe stress and adjustment disorder | 1 |
| Depressive disorders | |
| Moderate depressive disorder | 1 |
| Recurrent depressive disorder, current episode mild | 1 |
| Somatoform disorders | |
| Undifferentiated somatoform disorder | 1 |
| Somatoform autonomic dysfunction | 1 |
| Personality disorders | |
| Obsessive-compulsive personality disorder | 1 |
An individual may have one or more somatic diseases or psychiatric disorders.
Results of investigations of autonomic nervous system function and hypothalamic–pituitary–adrenal axis functioning, mean (range)
| Laboratory testing | |
| Rest | |
| Heart rate, bpm | 66 (59–69) |
| Root mean square of successive differences of adjacent RR-intervals, ms | 34 (16–88) |
| Baroreceptor sensitivity, ms/mmHg | 10 (6–17) |
| Systolic brachial blood pressure, mmHg | 129 (100–154) |
| Diastolic brachial blood pressure, mmHg | 80 (70–90) |
| Active orthostatic test, power of low frequency band to high frequency band in the spectral analysis of heart rate variability (LF/HF ratio) | |
| Supine | 4.3 (0.7–21.0) |
| Standing | 8.7 (1.0–23.0) |
| Home monitoring | |
| Heart rate variability in beat-to-beat R–R interval recording | |
| Percentage of recovery during sleep (recovery index) | 56.1 (22.0–89.7) |
| Salivary cortisol | |
| Evening sample, nmol/L | 6.2 (1.8–15.9) |
Average of the mean of three values within three days.
Average of the mean of two different evening samples.